Johnson & Johnson
Active …JNJ.XETRA
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through …
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
553.67B EUR
Healthcare
Drug Manufacturers - General
Germany
EUR
Common Stock
- Open
- —
- High
- —
- Low
- —
- Close / last
- —
- Volume
- —
- Prev close
- —
- Change
- —
- Change %
- —
- Session date
- —
- Quote time
- —
PE Ratio (TTM)
31.13
Forward PE
23.26
Earnings per Share
$7.38
Dividend per Share
$5.24
Market Cap
553.67B
EBITDA
34.87B
Profit Margin
0.2148%
Dividend Yield
0.02%
Price / Sales (TTM)
5.620x
EV / Revenue
6.930x
EV / EBITDA
19.990x
Revenue Growth (YoY)
0.066%
Earnings Growth (YoY)
-0.009%
Address
One Johnson & Johnson Plaza
New Brunswick
, NJ
08933
United States
Phone
732 524 0400Website
https://www.jnj.comEmployees
138200
Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Innovative Medicine and R&D
Born 1958
Mr. Dirk Brinckman
Chief Compliance Officer
Mr. James Swanson
Executive VP & Chief Information Officer
Born 1966
Mr. Joaquin Duato
CEO & Chairman
Born 1963
Mr. Joseph James Wolk CPA
Executive VP & CFO
Born 1967
Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer
Born 1973
Mr. Ryan Koors
Vice President of Investor Relations
Mr. Timothy Schmid
Executive VP & Worldwide Chairman of MedTech
Born 1970
Ms. Elizabeth Forminard J.D.
Executive VP & Chief Legal Officer
Born 1971
Ms. Kristen Blair Mulholland
Executive VP & Chief HR Officer
Born 1967
2026-07-15
2026-10-13
Recent quarters & estimate trends
View full earnings (112)| Period | EPS Act. | EPS Est. | Surprise |
|---|---|---|---|
| Sep 2026 | — | 2.42 | — |
| Jun 2026 | 1.95 | 2.85 | -31.56% |
| Mar 2026 | 1.83 | 2.68 | -31.72% |
| Dec 2025 | 1.80 | 2.47 | -27.04% |
| Sep 2025 | 1.82 | 2.76 | -34.22% |
| Jun 2025 | 2.02 | 2.68 | -24.71% |
| Mar 2025 | 4.31 | — | — |
| Dec 2024 | 1.33 | — | — |
Estimate trends
Dec 2027
—
Dec 2026
—
Sep 2026
—
Jun 2026
—